1Pool PE. The clinical significance of neurohormonal activation. ClinTher, 1997, 19,Suppl A:53.
2Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol producesdose-related improvements in left ventricular function and survival insubjects with chronic heart failure. MOCHA Investigators. Circula-tion, 1996,94(11):2807.
3The Cardiac Insufficiency Bisoprolol Study Ⅱ ( CIBIS- Ⅱ ): a ran-domized trial. Lancet, 1999,353(9146):9.
4MERIT-HF Study Group. Effect of metoprolol CR/XL in chronicheart failure. Lancet, 1999,353(9169) :2001.
5Eichhorn EJ, Stevenson LW. The ten most commonly asked ques-tions about Beta-Blockers for heart failure. Cardiol Rev, 1998,6(2):59.
6Willenheimer R. Left ventricular remodelling and dysfunction. Canthe process be prevented? Int J Cardiol, 2000,72(2): 143.
7Fagerberg B. The merit of beta(1)-blockade in heart failure. EurHeart J, 1999,20(24):1761.
8Brand E, Chtelain N,Mulatero P, et al. Structural Analysis and E-valuation of the Aldosterone Synthase Gene in Hypertension. Hyper-tension, 1998, 32:198.
9Kupari M, Hautanan A, Lankinan L, et al. Associations BetweenHuman Aldosterone Synthase (CYP) 11B2 Gene Polymorphisms andleft Ventricular Size, Mass and Function. Circulation, 1998, 97:569.
10Leary AC, Macdonald TM. Angiotensin II Type I Receptor Block-ade: A New Development In Cardiovascular Pharmacology. Int JClin Pract, 1998, 52(7):475.
